(0.15%) 5 139.00 points
(0.11%) 38 483 points
(0.23%) 17 887 points
(-0.23%) $83.66
(0.99%) $1.942
(0.31%) $2 354.50
(0.53%) $27.68
(1.72%) $937.95
(-0.19%) $0.933
(-0.32%) $10.99
(-0.31%) $0.798
(1.21%) $92.99
@ $25.11
发出时间: 15 Feb 2024 @ 04:41
回报率: 13.78%
上一信号: Feb 14 - 04:43
上一信号:
回报率: 3.95 %
Live Chart Being Loaded With Signals
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders...
Stats | |
---|---|
今日成交量 | 1.65M |
平均成交量 | 877 920 |
市值 | 2.19B |
EPS | $0 ( 2024-04-25 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.41 |
ATR14 | $0.0530 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-19 | Klein Matthew B. | Sell | 3 361 | Common Stock |
2024-04-17 | Pauwels Eric | Sell | 787 | Common Stock |
2024-04-17 | Klein Matthew B. | Sell | 1 307 | Common Stock |
2024-04-02 | Golden Lee Scott | Sell | 526 | Common Stock |
2024-02-15 | Utter Christine Marie | Buy | 2 900 | Common Stock |
INSIDER POWER |
---|
73.37 |
Last 98 transactions |
Buy: 1 039 114 | Sell: 204 439 |
音量 相关性
PTC Therapeutics Inc 相关性 - 货币/商品
PTC Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $937.82M |
毛利润: | $649.70M (69.28 %) |
EPS: | $-8.37 |
FY | 2023 |
营收: | $937.82M |
毛利润: | $649.70M (69.28 %) |
EPS: | $-8.37 |
FY | 2022 |
营收: | $698.80M |
毛利润: | $654.12M (93.61 %) |
EPS: | $-7.79 |
FY | 2021 |
营收: | $538.59M |
毛利润: | $506.27M (94.00 %) |
EPS: | $-7.26 |
Financial Reports:
No articles found.
PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。